Cormedix (Cormedix) Total Liabilities : $10.01 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cormedix Total Liabilities?

Cormedix's Total Liabilities for the quarter that ended in Mar. 2024 was $10.01 Mil.

Cormedix's quarterly Total Liabilities increased from Sep. 2023 ($8.23 Mil) to Dec. 2023 ($11.92 Mil) but then declined from Dec. 2023 ($11.92 Mil) to Mar. 2024 ($10.01 Mil).

Cormedix's annual Total Liabilities increased from Dec. 2021 ($6.15 Mil) to Dec. 2022 ($6.98 Mil) and increased from Dec. 2022 ($6.98 Mil) to Dec. 2023 ($11.92 Mil).

Cormedix Total Liabilities Historical Data

The historical data trend for Cormedix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Total Liabilities Chart

Cormedix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

5.83

5.09

6.15

6.98

11.92

Cormedix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															5.31	7.98	8.23	11.92	10.01

Cormedix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cormedix's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.401	+	(0.517	+	-5.5511151231258E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11.92

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	82.06	-	70.142
	=	11.92

Cormedix's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.534	+	(0.477	+	-1.4432899320127E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	10.01

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	68.024	-	58.013
	=	10.01

Cormedix Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cormedix's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cormedix (Cormedix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

19KA:Germany

Address

300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922

Website

https://www.cormedix.com

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Executives

Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry	officer: Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco	director, officer: Chief Executive Officer	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan	director	C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa	director	MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart	director	360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione	director	ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David	officer: EVP, Chief Financial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson	officer: EVP, Head of Clinical Ops.	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel	officer: EVP, Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz	director	SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan	director	700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L.	officer: Exec VP of Tech Operations	C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch	director, officer: Chief Executive Officer	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921